| Dr Victoria Norton Moore, MD | |
|
2000 Medical Pkwy Ste 304, Annapolis, MD 21401-3745 | |
| (410) 573-9530 | |
| (410) 573-9568 |
| Full Name | Dr Victoria Norton Moore |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 12 Years |
| Location | 2000 Medical Pkwy Ste 304, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548526452 | NPI | - | NPPES |
| 597014Y5Z | Other | MD | MEDICARE |
| CY310013 | Other | MD | BCBS |
| 597014ZDWS | Other | MD | MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | D81306 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Luminis Health Medical Group, Llc | 2860447315 | 431 |
News Archive
A group of researchers led by Assistant Professor WATABE Tadashi of the Graduate School of Medicine of Osaka University achieved the stable domestic production of automatic synthesis modules for positron emission tomography (PET) probe F-18 NKO-035, a LAT1-selective amino acid derivative radiolabeled with 18F, confirming its safety in first-in-human clinical studies conducted at Osaka University Hospital in November 2019.
Researchers at Rush University Medical Center have found that opioid use might increase a person's risk of developing pancreatic cancer.
As the COVID-19 pandemic rages on, researchers are working overtime to develop vaccines and therapies to thwart SARS-CoV-2, the virus responsible for the disease Many efforts focus on the coronavirus spike protein, which binds the angiotensin-converting enzyme 2 (ACE2) on human cells to allow viral entry.
Research reveals that most individuals with cancer have religious and spiritual beliefs, or derive comfort from religious and spiritual experiences. But what impact does this have on patients' health? Recent analyses of all published studies on the topic-which included more than 44,000 patients-shed new light on the associations of religion and spirituality with cancer patients' mental, social, and physical well-being.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 3 days ago
| Entity Name | Luminis Health Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073580205 PECOS PAC ID: 2860447315 Enrollment ID: O20050317000146 |
News Archive
A group of researchers led by Assistant Professor WATABE Tadashi of the Graduate School of Medicine of Osaka University achieved the stable domestic production of automatic synthesis modules for positron emission tomography (PET) probe F-18 NKO-035, a LAT1-selective amino acid derivative radiolabeled with 18F, confirming its safety in first-in-human clinical studies conducted at Osaka University Hospital in November 2019.
Researchers at Rush University Medical Center have found that opioid use might increase a person's risk of developing pancreatic cancer.
As the COVID-19 pandemic rages on, researchers are working overtime to develop vaccines and therapies to thwart SARS-CoV-2, the virus responsible for the disease Many efforts focus on the coronavirus spike protein, which binds the angiotensin-converting enzyme 2 (ACE2) on human cells to allow viral entry.
Research reveals that most individuals with cancer have religious and spiritual beliefs, or derive comfort from religious and spiritual experiences. But what impact does this have on patients' health? Recent analyses of all published studies on the topic-which included more than 44,000 patients-shed new light on the associations of religion and spirituality with cancer patients' mental, social, and physical well-being.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Victoria Norton Moore, MD Po Box 12622, Belfast, ME 04915-4017 Ph: (410) 573-9530 | Dr Victoria Norton Moore, MD 2000 Medical Pkwy Ste 304, Annapolis, MD 21401-3745 Ph: (410) 573-9530 |
News Archive
A group of researchers led by Assistant Professor WATABE Tadashi of the Graduate School of Medicine of Osaka University achieved the stable domestic production of automatic synthesis modules for positron emission tomography (PET) probe F-18 NKO-035, a LAT1-selective amino acid derivative radiolabeled with 18F, confirming its safety in first-in-human clinical studies conducted at Osaka University Hospital in November 2019.
Researchers at Rush University Medical Center have found that opioid use might increase a person's risk of developing pancreatic cancer.
As the COVID-19 pandemic rages on, researchers are working overtime to develop vaccines and therapies to thwart SARS-CoV-2, the virus responsible for the disease Many efforts focus on the coronavirus spike protein, which binds the angiotensin-converting enzyme 2 (ACE2) on human cells to allow viral entry.
Research reveals that most individuals with cancer have religious and spiritual beliefs, or derive comfort from religious and spiritual experiences. But what impact does this have on patients' health? Recent analyses of all published studies on the topic-which included more than 44,000 patients-shed new light on the associations of religion and spirituality with cancer patients' mental, social, and physical well-being.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 3 days ago
Richard G. Welch, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2000 Medical Pkwy, Ste 304, Annapolis, MD 21401 Phone: 410-573-9530 Fax: 410-573-9569 | |
Monica B Jones, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2000 Medical Pkwy Ste 200, Annapolis, MD 21401 Phone: 443-481-3493 Fax: 443-481-6705 | |
Dr. Joy'el B Ballard, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2000 Medical Pkwy, Ste. 304, Annapolis, MD 21401 Phone: 410-573-9530 Fax: 410-573-9568 | |
Dr. Christine Ajjan Laky, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 185 Harry S Truman Pkwy Ste 120, Annapolis, MD 21401 Phone: 410-224-4442 Fax: 410-224-8898 | |
Margaret Jessica Keith, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2003 Medical Pkwy, Annapolis, MD 21401 Phone: 410-571-9700 | |
Elizabeth T. Greeley, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 820 Bestgate Rd, Suites 2c & 2d, Annapolis, MD 21401 Phone: 410-224-4442 Fax: 410-224-8898 | |
Mark L. Repka, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2000 Medical Pkwy, Ste 304, Annapolis, MD 21401 Phone: 410-573-9530 Fax: 410-573-9569 |